Abstract
Cytarabine is the most effective agent known for the treatment of acute myeloid leukemia. Its antitumor effect is expressed by combining with DNA during replication and then destroying the DNA chain. However, cytarabine has only limited activity against most solid tumors, including squamous cell carcinoma of the head and neck. The reason for this is thought to be that in cell lines of solid tumors the expression of cytidine deaminase, an enzyme that degrades cytarabine, is high, whereas the expression of deoxycytidine kinase (dCK), which phosphorylates cytarabine (a prodrug), is weak. To determine whether head and neck squamous cell carcinomas can be made more sensitive to the cytotoxic effects of cytarabine by shifting the balance from the degradative to the activation pathway. Human SCC-25 squamous carcinoma cells were transfected by either retroviral vector or adenoviral vector containing DCK gene and were identified for dCK expression by Northern blot analysis. In vitro cytotoxic assay after cytarabine exposure was performed using these cells. Both retroviral and adenoviral vector-mediated transduction of the dCK complementary DNA resulted in marked sensitization of tongue squamous carcinoma cell lines to the cytotoxic effects of cytarabine in vitro. The dCK-cytarabine system may be a useful approach for gene therapy of squamous cell carcinomas of the head and neck.
Highlights
Cytarabine is the most effective agent known for the treatment of acute myeloid leukemia.Its antitumor effect is expressed by combining withDNA during replication and destroying the DNA chain
In vitro cytotoxic assay after cytarabine exposure was performed using these cells. Both retroviral and adenoviral vector-mediated transduction of the deoxycytidine kinase (dCK) complementary DNA resulted in marked sensitization of tongue squamous carcinoma cell lines to the cytotoxic effects of cytarabine in vitro
The dCK-cytarabine system may be a useful approach for gene therapy of squamous cell carcinomas of the head and neck
Summary
Cytarabine is the most effective agent known for the treatment of acute myeloid leukemia.Its antitumor effect is expressed by combining withDNA during replication and destroying the DNA chain. Cytarabine is the most effective agent known for the treatment of acute myeloid leukemia. Its antitumor effect is expressed by combining with. DNA during replication and destroying the DNA chain. Cytarabine has only limited activity against most solid tumors, including squamous cell carcinoma of the head and neck. The reason for this is thought to be that in cell lines of solid tumors the expression of cytidine deaminase, an enzyme that degrades cytarabine, is high, whereas the expression of deoxycytidine kinase (dCK), which phosphorylates cytarabine (a prodrug), is weak
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Archives of Otolaryngology–Head & Neck Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.